The offering closes the next day, so the dilution is immediate. Monitor for any subsequent insider selling or additional capital needs; the cash runway extension into 2029 reduces near-term financing risk but the dilutive overhang may pressure the stock near-term.
Price Chart
Executive Summary
Recursion Pharmaceuticals priced a $200 million underwritten public offering of 61.54 million shares at $3.25 per share, diluting existing shareholders by approximately 23% based on pre-offering shares outstanding. The offering, which closed the next day, extends cash runway into 2029 but represents a significant near-term dilution event.
Key Financial Metrics
Key Facts
- Offering of 61,540,000 shares at $3.25 per share for gross proceeds of ~$200 million
- Expected to close on October 16, 2026
- Underwriters include Leerink Partners, Goldman Sachs, Morgan Stanley, Evercore, and Needham
- Participation from Janus Henderson, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management
- Prospectus supplement filed on October 15, 2026 under existing S-3 shelf registration
Financial Impact
~$200 million gross proceeds; dilution of ~23% based on pre-offering share count (61.54M new shares vs. ~268M shares outstanding prior to offering)
Risk Factors
- Immediate dilution of ~23% for existing shareholders
- Potential downward pressure on stock price from increased float
- Offering priced at $3.25, near recent trading levels, offering no premium cushion
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381643 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 424B5 | $3.47 $3.58 | ▼ −3.32% | ▼ −3.23% | $3.80 (−9.67%) |
Oct 15, 2026 11d ago | 8-K | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $3.80 (+8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | 424B5 | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $3.80 (+8.65%) |
Oct 6, 2026 20d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $3.80 (−17.93%) |
Oct 6, 2026 20d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $3.80 (−17.93%) |
Sep 21, 2026 5w ago | 8-K | $3.97 $3.70 | ▼ −6.80% | ▼ −5.78% | $3.80 (−4.28%) |
Sep 10, 2026 6w ago | Insider Cluster | $3.20 $3.83 | ▲ +19.69% | ▲ +20.03% | $3.80 (+18.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers